APA (7th ed.) Citation

SD, H., YS, W., HY, Z., YY, Z., QM, W., YX, M., . . . WF, F. (2026). Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase I and phase II trials. Annals of oncology : official journal of the European Society for Medical Oncology, 37(6), 813. https://doi.org/10.1016/j.annonc.2026.01.009

Chicago Style (17th ed.) Citation

SD, Hong, et al. "Izalontamab Brengitecan (Iza-bren; BL-B01D1), a First-in-class EGFR-HER3 Bispecific Antibody-drug Conjugate, for Patients with EGFR-mutated NSCLC: Pooled Analysis of Phase I and Phase II Trials." Annals of Oncology : Official Journal of the European Society for Medical Oncology 37, no. 6 (2026): 813. https://doi.org/10.1016/j.annonc.2026.01.009.

MLA (9th ed.) Citation

SD, Hong, et al. "Izalontamab Brengitecan (Iza-bren; BL-B01D1), a First-in-class EGFR-HER3 Bispecific Antibody-drug Conjugate, for Patients with EGFR-mutated NSCLC: Pooled Analysis of Phase I and Phase II Trials." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 37, no. 6, 2026, p. 813, https://doi.org/10.1016/j.annonc.2026.01.009.